Summary & Overview
Other Kidney and Urinary Tract Procedures with CC: Inpatient Reimbursement Overview
DRG 674 covers other kidney and urinary tract procedures performed during inpatient stays when a Complication or Comorbidity is present, representing moderate-severity genitourinary surgical cases. It matters for inpatient reimbursement because the Complication or Comorbidity designation increases expected resource use and thus influences Medicare payment under the inpatient prospective payment system.
DRG 674 Overview
DRG 674 includes inpatient admissions for other kidney and urinary tract procedures when a Complication or Comorbidity is present, covering a range of genitourinary surgical interventions that do not meet higher-severity groupings. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity elevates reimbursement relative to cases without such comorbidity, reflecting greater expected resource use and clinical complexity. Understanding the procedure types and comorbidity impact aids accurate coding and hospital case-mix reporting. Payments for cases assigned here are used in inpatient prospective payment calculations by Centers for Medicare & Medicaid Services.
Clinical Trials
- Acute perioperative safety and complication-reduction trials: studies testing perioperative protocols (such as fluid management strategies, antibiotic timing/duration, or minimally invasive versus open approaches) for patients undergoing non-major kidney and urinary tract procedures with serious comorbidities. These trials enroll inpatients admitted for procedures like ureteral surgery, partial nephrectomy for small masses, or complex endoscopic stone removal who have complicating conditions (eg, chronic kidney disease, diabetes, or anticoagulation). Results inform clinicians on best practices to reduce immediate postoperative complications, length of stay, and readmissions — outcomes that directly affect DRG payments and resource use for providers and payers.
- Comparative effectiveness studies of procedural approaches and technologies: pragmatic randomized or observational studies comparing different procedural techniques (for example, various endoscopic approaches, laser settings, or adjunctive stent strategies) in heterogeneous inpatient populations with obstructive uropathy, recurrent stones, or benign strictures. These studies focus on metrics such as procedure success rates, need for reintervention, perioperative renal function changes, and short-term morbidity in real-world hospital settings. Findings guide hospital policy and payer decisions about preferred technologies and pathways that balance clinical benefit with costs and can influence utilization within this DRG.
- Post-discharge outcomes and care coordination research: longitudinal cohort and implementation studies examining post-discharge renal outcomes, unplanned emergency visits, and adherence to follow-up in patients treated for complex urinary tract conditions with complications (the CC in this DRG), including the impact of transitional care interventions (eg, early outpatient nephrology/urology follow-up, remote monitoring of renal function, or patient education bundles). These studies enroll patients after inpatient procedures to measure 30- and 90-day readmissions, progression of kidney injury, and patient-reported outcomes. Evidence from this research is relevant to providers and payers because reducing readmissions and long-term renal deterioration influences total episode costs and quality metrics tied to DRG performance.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.